227 related articles for article (PubMed ID: 19638542)
1. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer.
Mhawech-Fauceglia P; Ali L; Cheney RT; Groth J; Herrmann FR
J Clin Pathol; 2009 Aug; 62(8):710-4. PubMed ID: 19638542
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
3. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
4. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
5. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
6. Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?
Gudjónsson S; Bendahl PO; Chebil G; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W; Liedberg F
Scand J Urol Nephrol; 2011 Sep; 45(4):270-7. PubMed ID: 21504385
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
9. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: correlation with clinical variables and prognostic significance.
Shen YJ; Ye DW; Yao XD; Trink B; Zhou XY; Zhang SL; Dai B; Zhang HL; Zhu Y; Guo Z; Wu G; Nagpal J
BJU Int; 2008 Jan; 101(1):113-9. PubMed ID: 17941920
[TBL] [Abstract][Full Text] [Related]
11. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
Wild PJ; Kunz-Schughart LA; Stoehr R; Burger M; Blaszyk H; Simon R; Gasser T; Mihatsch M; Sauter G; Hartmann A
Int J Oncol; 2005 Aug; 27(2):385-91. PubMed ID: 16010419
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
13. Parafibromin expression in breast cancer: a novel marker for prognostication?
Selvarajan S; Sii LH; Lee A; Yip G; Bay BH; Tan MH; Teh BT; Tan PH
J Clin Pathol; 2008 Jan; 61(1):64-7. PubMed ID: 17468290
[TBL] [Abstract][Full Text] [Related]
14. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis.
Mhawech-Fauceglia P; Fischer G; Alvarez V; Ahmed A; Herrmann FR
BJU Int; 2007 Nov; 100(5):1182-7. PubMed ID: 17645415
[TBL] [Abstract][Full Text] [Related]
15. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
16. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor receptor (p75 NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma.
Søland TM; Brusevold IJ; Koppang HS; Schenck K; Bryne M
Histopathology; 2008 Jul; 53(1):62-72. PubMed ID: 18540978
[TBL] [Abstract][Full Text] [Related]
19. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Aoki S; Yamada Y; Nakamura K; Taki T; Tobiume M; Honda N
Oncol Rep; 2006 Aug; 16(2):279-84. PubMed ID: 16820903
[TBL] [Abstract][Full Text] [Related]
20. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma.
Adams H; Tzankov A; Lugli A; Zlobec I
J Clin Pathol; 2009 Nov; 62(11):986-97. PubMed ID: 18977805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
